Outputs (2)

Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical ?-Blockers (2020)
Journal Article
Baker, J. G., Fromont, C., Bruder, M., Thompson, K. S., Kellam, B., Hill, S. J., …Fischer, P. M. (2020). Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers. ACS Pharmacology & Translational Science, 3(4), 737-748. https://doi.org/10.1021/acsptsci.0c00051

© 2020 American Chemical Society. For disorders of the skin, eyes, ears, and respiratory tract, topical drugs, delivered directly to the target organ, are a therapeutic option. Compared with systemic oral therapy, the benefits of topical treatments i... Read More about Using Esterase Selectivity to Determine the in Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical ?-Blockers.

The affinity and selectivity of ?-adrenoceptor antagonists, antidepressants, and antipsychotics for the human ?1A, ?1B, and ?1D-adrenoceptors (2020)
Journal Article
Proudman, R. G. W., Pupo, A. S., & Baker, J. G. (2020). The affinity and selectivity of ?-adrenoceptor antagonists, antidepressants, and antipsychotics for the human ?1A, ?1B, and ?1D-adrenoceptors. Pharmacology Research and Perspectives, 8(4), https://doi.org/10.1002/prp2.602

© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. α1-adrenoceptor antagonists are widely used for hype... Read More about The affinity and selectivity of ?-adrenoceptor antagonists, antidepressants, and antipsychotics for the human ?1A, ?1B, and ?1D-adrenoceptors.